Alnylam Pharmaceuticals has promoted Barry Greene from COO to president and COO, the firm announced last week. He will continue to report to CEO John Maraganore. Prior to Alnylam, Greene was general manager of oncology at Millennium Pharmaceuticals.
Robert Saltmarsh, vice president and chief financial officer at Nanogen, will retire from his position at the end of February 2008, the firm said last week. Saltmarsh will continue to consult with Nanogen through the end of next year as needed.
Nick Venuto, executive director of finance, has been named as Saltmarsh's successor. Venuto has been responsible for financial operations and reporting for the last four years.